Medical technology company Bioretec announces that the U.S. agency CMS has finally confirmed special Medicare reimbursement for the RemeOs Screw LAG Solid implant.
The decision means that U.S. hospitals and outpatient clinics can receive separate reimbursement for the implant in addition to the regular reimbursement for the procedure.
The reimbursement status, known as transitional pass-through payment, applies from October 1, 2025 to September 30, 2028, which is the maximum permitted period of three years.
The implant is a biodegradable screw for bone fixation and has previously received FDA Breakthrough Device status.
Bioretec CEO Sarah van Hellenberg Hubar-Fisher says that the decision gives U.S. healthcare providers clearer reimbursement conditions and may facilitate access to the technology for Medicare patients.
